BAY 17403/ FORT-1
A randomized, open Label, multicenter Phase 2/3 study to evaluate the efficiacy and safety of regaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received Prior platinumcontaining chemotherapy.
Short title: Phase 2/3 study of rogaratinib (BAY 1163877) vs chemotherapy 

2nd lineoffenNiegisch/ Lorch/ Hiester

TITAN-TCC (Urothel-CA)
A Phase II single arm clinical Trial of a Tailored Immuno Therapy Approach of Nivolumab in subjects with metastatic or advanced Transitional Cell Carinoma

1st, 2nd, 3rd lineoffenLorch/ Niegisch/ Hiester
SAKK 06/17
Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single arm Phase II trial
neo - + adjuvantStart 06.12.2018Niegisch/ Lorch/ Hiester
MediathekInformation und Wissen
LageplanSo finden Sie uns